Evidence map›Paper›PMID 39309855›Full record

ArticleHeliyon2024

Fei Jin Sheng formula and its effectiveness in treating advanced non-small cell lung cancer: An observational study.

Zhen Yan, Wen-Cang Gao, Xiao-Xiao Wang, Hong-Quan Xu, Qian Li, Jian-Xiang Chen, De-Xiang Pang, Tian Xie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhen YanFirst Clinical Medical Institute, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210023, China.
Wen-Cang GaoDepartment of Oncology, The Second Affiliated Hospital of Zhejiang Chinese Medicine University, Hangzhou, Zhejiang, 310005, China.
Xiao-Xiao WangDepartment of GCP, Jiangsu Provincial Hospital of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210029, China.
Hong-Quan XuSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.
Qian LiSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.
Jian-Xiang ChenSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.
De-Xiang PangDepartment of Oncology, The Second Affiliated Hospital of Zhejiang Chinese Medicine University, Hangzhou, Zhejiang, 310005, China.
Tian XieFirst Clinical Medical Institute, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210023, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study involved evaluating the efficacy of the Feijinsheng formula in the therapeutic management of patients with advanced non-small cell lung cancer (NSCLC). Methods: We extracted the medical records of patients with advanced NSCLC undergoing treatment in the oncology department at the Second Affiliated Hospital of Zhejiang Chinese Medicine University from the medical record system. After applying inclusion and exclusion criteria, clinical data of 150 patients were collected. The patients were stratified into two groups based on their usage of the Feijinsheng formula, comprising 69 cases in the Exposed group and 81 cases in the Control group. A comparative analysis of the survival time difference between the two groups was conducted. Results: The data between the two groups exhibited similarity ( Conclusion: The Feijinsheng formula extended the duration of survival of patients with advanced NSCLC.

Indexed as

Feijinsheng formulaNon-small cell lung cancerObjective remission rateOverall survivalRetrospective clinical researchTraditional Chinese medicine

Identifiers

PMID39309855
PMCPMC11416240

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.